· 个股论点
$NBIS 财报大幅超出预期，年化经常性收入(ARR)达70-90亿美元，并与Meta达成30亿美元的超大规模云厂商(hyperscaler)交易。他们还增加了企业客户Cursor。尽管如此，在财报电话会议前股价目前下跌1.77%。为什么？稀释~27亿美元，2500万股通过市场发行(ATM)稀释，将于11月12日提交。这意味着价值27亿美元的股票（按当前价格）可以在公开市场按当前价格出售，而非可转换票据（首选结构），这很可能是股价尚未上涨20%的主要原因。这会影响短期股价，但此次发行后公司基本面依然惊人，拥有卓越的未来收入增长。例如看看Rocketlab或其他通过此举补充增长的公司。如果有更多时间，我也会深入分析财务数据。但仅2026年的70-90亿美元ARR（许多分析师预期在2028年之后），是非常看多的。
$NBIS earnings report blew away expectations with $7-9B ARR and a $3B hyperscaler deal with Meta. They also added to their enterprise client list with Cursor. Despite that, stock is down -1.77% currently before their earnings call. Why? Dilution~$2.7B 25M share dilution ATM offering that will be filed Nov 12th. Meaning 2.7B worth of shares (at current prices) can be sold in the open market at current prices vs. convertible notes (preferred structure), which is the most likely reason it's not up 20% by now. It affect share price short term, but the company fundamentals after this offering is incredible with amazing forward revenue growth. Eg. look at Rocketlab or others that did this to supplement growth. Will also delve into financial data given more time. But the $7-9 billion ARR for 2026 alone (which many analysts expected in 2028+), is insanely bullish.